Get the Stockscreener App
0.1173
45.92%
-0.0996
Applied Therapeutics Inc stock is traded at $0.1173, with a volume of 37.84M.
It is down -45.92% in the last 24 hours and down -87.11% over the past month.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
See More
Previous Close:
$0.2169
Open:
$0.12715
24h Volume:
37.84M
Relative Volume:
2.83
Market Cap:
$16.93M
Revenue:
-
Net Income/Loss:
$-119.76M
P/E Ratio:
-0.0869
EPS:
-1.35
Net Cash Flow:
$-55.17M
1W Performance:
-45.84%
1M Performance:
-87.11%
6M Performance:
-67.86%
1Y Performance:
-89.71%
1-Day Range:
$0.11
$0.1293
1-Week Range:
$0.11
$0.258
52-Week Range:
$0.11
$1.50
Applied Therapeutics Inc Stock (APLT) Company Profile
Name
Applied Therapeutics Inc
Sector
Industry
Phone
212-220-9226
Address
545 FIFTH AVENUE, SUITE 1400, NEW YORK, NY
Compare APLT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APLT
Applied Therapeutics Inc
|
0.1173 | 31.30M | 0 | -119.76M | -55.17M | -1.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Applied Therapeutics Inc Stock (APLT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-03-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-23-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Dec-02-24 | Downgrade | UBS | Buy → Neutral |
| Nov-29-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-31-24 | Initiated | William Blair | Outperform |
| Mar-26-24 | Initiated | RBC Capital Mkts | Outperform |
| Feb-22-24 | Initiated | Leerink Partners | Outperform |
| Jan-04-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Aug-27-21 | Downgrade | Goldman | Neutral → Sell |
| Jun-25-21 | Resumed | Goldman | Neutral |
| Oct-08-20 | Initiated | Truist | Buy |
| Apr-22-20 | Initiated | Goldman | Buy |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jun-10-19 | Initiated | Citigroup | Buy |
| Jun-10-19 | Initiated | Cowen | Outperform |
| Jun-10-19 | Initiated | Robert W. Baird | Outperform |
View All
Applied Therapeutics Inc Stock (APLT) Latest News
SHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger--ALEX, DVS, DXLG, and APLT - Benzinga
Applied Therapeutics stock rating downgraded to Neutral by Baird - Investing.com Nigeria
Cycle buying Applied Therapeutics to develop CNS drugs - BioWorld MedTech
S&P 500 Down 1%; Broadcom Earnings Top Views - Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Cycle Pharma to acquire Applied Therapeutics - The Pharma Letter
Cycle Group Holdings Limited entered into a definitive agreement to acquire Applied Therapeutics, Inc. for $13.4 million. - marketscreener.com
Dow Rises Over 100 Points; Lululemon Posts Upbeat Q3 Earnings - Benzinga
Applied Therapeutics (APLT) Stock News Today: Cycle Deal Details, CVR Upside, and Analyst Outlook (Dec. 12, 2025) - ts2.tech
RBC Cuts Price Target on Applied Therapeutics to $0.25 From $1, Keeps Sector Perform, Speculative Risk - marketscreener.com
APLT Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Applied Therapeutics, Inc. is Fair to Shareholders - The AI Journal
Applied Therapeutics Announces Merger with Cycle Group - TipRanks
Applied Therapeutics plunges after UK's Cycle Group to buy co - TradingView — Track All Markets
Why Lululemon Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket - Benzinga
Applied Therapeutics stock price target lowered by RBC on Cycle acquisition - Investing.com UK
Applied Therapeutics To Be Acquired By Privately Held Cycle Group - Nasdaq
Cycle Pharmaceuticals acquiring Applied Therapeutics - MSN
Cycle Group to Acquire Applied Therapeutics (APLT) in Strategic Deal - GuruFocus
Cycle Pharmaceuticals to Acquire Applied Therapeutics - The Manila Times
Cycle to buy Applied Therapeutics (Nasdaq: APLT) in cash, CVR deal closing in Q1 2026 - Stock Titan
Published on: 2025-12-05 04:31:49 - Newser
Is Applied Therapeutics Inc. stock a buy on dipsJuly 2025 Gainers & Weekly Sector Rotation Insights - Newser
Is Applied Therapeutics Inc. (2UV) stock prepared for digital transition2025 Short Interest & Verified Technical Signals - Newser
Can Applied Therapeutics Inc. (2UV) stock surprise markets with earningsPortfolio Growth Summary & High Accuracy Buy Signal Tips - Newser
How Applied Therapeutics Inc. (2UV) stock moves in volatile trading sessions2025 Trade Ideas & Real-Time Stock Movement Alerts - Newser
Can Applied Therapeutics Inc. (2UV) stock double in coming yearsWeekly Profit Recap & AI Optimized Trade Strategies - Newser
Applied Therapeutics stock rating downgraded by Leerink Partners on cash concerns - Investing.com Nigeria
APLT Downgraded by Leerink Partners: Key Analyst Update | APLT S - GuruFocus
Why Applied Therapeutics Inc. (2UV) stock fits value portfoliosTrade Performance Summary & Low Volatility Stock Suggestions - Newser
Why Applied Therapeutics Inc. (2UV) stock trades below fair value2025 Biggest Moves & Fast Moving Market Watchlists - Newser
What analysts say about Applied Therapeutics Inc stockHead and Shoulders Patterns & Minimal Investment Trading - earlytimes.in
Would You Still Hold Applied Therapeutics Stock If It Fell Another 30%? - Trefis
Applied Therapeutics (APLT) Upgraded to Buy: Here's Why - MSN
Applied Therapeutics Reports Third Quarter 2025 Financial Results - ADVFN
Finance Watch: Poxel Pulls Back From The Brink With Recovery Plan - Citeline News & Insights
Applied Therapeutics To Lay Off Nearly Half Its Staff, Board Explores M&A Options - MSN
Applied Therapeutics (APLT) Stock Price, Quote, News & History - Benzinga
Applied Therapeutics Investors Get 1st OK For $15M Deal - Law360
Why Applied Therapeutics Inc. stock could see breakout soonMarket Trend Review & Weekly Momentum Stock Picks - newser.com
Applied Therapeutics explores strategic alternatives amid workforce cuts By Investing.com - Investing.com Nigeria
Applied Therapeutics Announces Corporate Updates - Investing News Network
Applied Therapeutics, Inc. Initiates Strategic Alternatives Review - TradingView
Applied Therapeutics explores strategic alternatives amid workforce cuts - Investing.com
APLT Evaluates Strategic Options as Workforce Reductions Announced - GuruFocus
APLT Evaluates FDA Meeting Outcomes for Govorestat Development P - GuruFocus
What data driven models say about Applied Therapeutics Inc.’s future - newser.com
Applied Therapeutics (Nasdaq: APLT) to Explore Strategic Alternatives, Reduce Workforce 46% - Stock Titan
How Applied Therapeutics Inc. stock reacts to inflationary pressuresWeekly Trade Analysis & High Accuracy Swing Entry Alerts - newser.com
Applied Therapeutics Inc Stock (APLT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Applied Therapeutics Inc Stock (APLT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Funtleyder Leslie D. | See Remarks |
Mar 04 '25 |
Sale |
0.44 |
14,502 |
6,381 |
390,459 |
| Chinoporos Constantine | See Remarks |
Mar 04 '25 |
Sale |
0.44 |
447 |
197 |
271,436 |
| Funtleyder Leslie D. | See Remarks |
Feb 06 '25 |
Sale |
0.61 |
22,950 |
14,000 |
404,961 |
| Perfetti Riccardo | Chief Medical Officer |
Feb 06 '25 |
Sale |
0.61 |
86,078 |
52,508 |
900,775 |
| Chinoporos Constantine | See Remarks |
Feb 06 '25 |
Sale |
0.61 |
28,117 |
17,151 |
271,883 |
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):